Work

Azetidinones as vasopressin V1a antagonists

Year: 2006

Type: article

Source: Bioorganic & Medicinal Chemistry

DOI: 10.1016/j.bmc.2006.12.031

Authors: Christophe D. Guillon, Gary A. Koppel, Michael J. Brownstein, Michael O. Chaney, Craig F. Ferris, Shi-fang Lu, Karine M. Fabio, Marvin J. Miller, Ned D. Heindel, David C. Hunden, Robin D.G. Cooper, Stephen W. Kaldor, Jeffrey J. Skelton, Bruce A. Dressman, Michael P. Clay, Mitchell I. Steinberg, Robert F. Bruns, Neal G. Simon

Institutions: Lehigh University, Azevan Pharmaceuticals (United States), University of Massachusetts Chan Medical School, University of Notre Dame, Eli Lilly (United States)

Language: English

Topic: Neuroendocrine regulation and behavior

Subfield: Social Psychology

Field: Psychology

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Eli Lilly and Company, National Institutes of Health, National Institute of Mental Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development

Awards: G1199033962, G2344682237, G2445531290, G2478742992, G2802430249, TREATING SELF-ABUSE IN AUTISM AND MENTAL RETARDATION, Treating Self-Abuse in Autism and Mental Retardation, Faculty Research Enhancement Support Program For Oakwood, A Potential New Drug for Depression, G7154730416, A New Drug for Depression, G8129486018

OpenAlex ID: W2054829179

FWCI: 2.578

Cites: 22

Cited by: 74

Related to: 10